Adding the monoclonal antibody drug trastuzumab — already used to treat certain breast cancers — to the chemotherapy regimen of women with a rare form of
uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.